Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: COLLABORATIONS PHARMACEUTICALS, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2025-09-29 to 2026-12-29
Current total value of award: $1999195.12
Description: IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U